News und Analysen

Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical

Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2023. The company narrowed its 2023 revenue guidance⁽⁴⁾ range to $67 to $70 billion, while maintaining its outlook for

Agilent Technologies Inc. (NYSE: A) today released its 2022 ESG report on the company’s work supporting customers with their sustainability initiatives while advancing its own internal

Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology

Pfizer Inc. (NYSE: PFE) today announced the company’s immediate efforts to provide relief and repair the damage caused to its manufacturing facility in Rocky Mount, North Carolina after a violent

Pfizer Inc. (NYSE: PFE) today announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being

Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2023 after the stock market closes on Tuesday, Aug. 15. In addition, the company will host a

Agilent Technologies Inc. (NYSE: A) today announced the company has achieved certification as a Great Place to Work®. The recognition reflects Agilent's commitment to creating a positive work

Agilent Technologies Inc. (NYSE: A) today announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range of prebuilt experiment templates for common

Agilent Technologies Inc. (NYSE: A) has announced the receipt of three 2023 Scientists’ Choice Awards; Best New Spectroscopy Product of 2022, Analytical Science Video of the Year, Analytical

Two of CenterWell Home Health’s four regions have been recognized by the American Diabetes Association (ADA) for delivering the best in self-management education and support for people with

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for fidanacogene elaparvovec for the

Pfizer Inc. (NYSE: PFE) today announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved LITFULO^™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 third-quarter 2023 dividend on the company’s common stock, payable September 5, 2023, to holders of the Common

Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 1, 2023. The purpose

Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf

Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and

Agilent Technologies Inc. (NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories’ perceptions

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the

Agilent Technologies Inc. (NYSE: A) today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell

Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS) analysis using the United States (US)

Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the